24-Jul-2026
RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
TipRanks (Thu, 23-Jul 8:25 AM ET)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Thu, 16-Jul 7:00 AM ET)
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
Globe Newswire (Mon, 13-Jul 7:00 AM ET)
EyePoint Announces Participation at Upcoming Investor Conferences
Globe Newswire (Tue, 19-May 7:00 AM ET)
Globe Newswire (Thu, 14-May 7:00 AM ET)
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Globe Newswire (Wed, 6-May 7:00 AM ET)
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Globe Newswire (Wed, 29-Apr 7:00 AM ET)
EyePoint Extends Cash Runway to Q4 2027 as Phase 3 DURAVYU Trials Accelerate for Wet AMD and DME
Market Chameleon (Wed, 5-Nov 4:39 AM ET)
EyePoint’s $150 Million Public Offering Fuels Late-Stage Trials and Pipeline Expansion
Market Chameleon (Wed, 15-Oct 4:22 AM ET)
Market Chameleon (Wed, 5-Feb 3:40 AM ET)
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Eyepoint trades on the NASDAQ stock market under the symbol EYPT.
As of July 24, 2026, EYPT stock price declined to $12.19 with 1,340,885 million shares trading.
EYPT has a beta of 1.89, meaning it tends to be more sensitive to market movements. EYPT has a correlation of 0.13 to the broad based SPY ETF.
EYPT has a market cap of $1.02 billion. This is considered a Small Cap stock.
Last quarter Eyepoint reported $696,000 in Revenue and -$.99 earnings per share. This beat revenue expectation by $353,736 and missed earnings estimates by -$.19.
In the last 3 years, EYPT traded as high as $30.99 and as low as $3.91.
The top ETF exchange traded funds that EYPT belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.
EYPT has underperformed the market in the last year with a price return of +16.2% while the SPY ETF gained +17.7%. EYPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.5% and -17.2%, respectively, while the SPY returned +3.8% and -2.1%, respectively.
EYPT support price is $11.85 and resistance is $13.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EYPT shares will trade within this expected range on the day.